AR070862A1 - Terapia de combinacion con antagonistas de c- met y her - Google Patents
Terapia de combinacion con antagonistas de c- met y herInfo
- Publication number
- AR070862A1 AR070862A1 ARP090100816A ARP090100816A AR070862A1 AR 070862 A1 AR070862 A1 AR 070862A1 AR P090100816 A ARP090100816 A AR P090100816A AR P090100816 A ARP090100816 A AR P090100816A AR 070862 A1 AR070862 A1 AR 070862A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- sequence
- antibody
- antagonist
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Uso de una cantidad terapéuticamente eficaz de un antagonista de c-met y un antagonista de HER, para la manufactura de un medicamento para el tratamiento de cáncer en un sujeto. Reivindicacion 2: El uso de la reivindicacion 1, donde el antagonista de c-met es un anticuerpo. Reivindicacion 3: El uso de la reivindicacion 2, donde el anticuerpo es un anticuerpo monovalente. Reivindicacion 5: El uso de la reivindicacion 3, donde el anticuerpo comprende (a) un primer polipéptido que comprende un dominio variable de cadena pesada que tiene la secuencia: QVQLQQSGPELVRPGASVKMSCRASGYTFTSYWLHWVKQRPGQGLEWIGMIDPSNSDTRFNPNFKDKATLNVDRSSNTAYMLLSSLTSADSAVYYCATYGSYVSPLDYWGQGTSVTVSS (SEC. ID. Ns 35), secuencia CH1 representada en la figura 12 (SEC. ID. Ns 32) y la secuencia Fc representada en la figura 12 (SEC. ID. Ns 33); y (b) un segundo polipéptido que comprende un dominio variable de cadena liviana que tiene la secuencia: DIMMSQSPSSLTVSVGEKVTVSCKSSQSLLYTSSQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTITSVKADDLAVYYCQQYYAYPWTFGGGTKLEIK (SEC. ID. Ns 36) y secuencia CL1 representada en la figura 12 (SEC. ID. Ns 24); y (c) un tercer polipéptido que comprende la secuencia Fc representada en la figura 13 (SEO. ID. Ns 34). Reivindicacion 8: El uso de la reivindicacion 1, donde el antagonista de HER es un anticuerpo. Reivindicacion 12: El uso de la reivindicacion 1, donde el cáncer se selecciona del grupo que consiste en cáncer de mama, cáncer colorrectal, cáncer rectal, cáncer de pulmon de células no pequenas, linfoma no hodgkiniano, cáncer de célula renal, cáncer de prostata, cáncer de hígado, cáncer de páncreas, sarcoma de tejido blando, sarcoma de Kaposi, carcinoma carcinoide, cáncer de cabeza y cuello, cáncer gástrico, melanoma, cáncer de ovario, mesotelioma y mieloma multiple.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3445308P | 2008-03-06 | 2008-03-06 | |
US4443308P | 2008-04-11 | 2008-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070862A1 true AR070862A1 (es) | 2010-05-12 |
Family
ID=40672191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100816A AR070862A1 (es) | 2008-03-06 | 2009-03-06 | Terapia de combinacion con antagonistas de c- met y her |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090226455A1 (es) |
EP (1) | EP2260056A1 (es) |
JP (1) | JP2011513432A (es) |
AR (1) | AR070862A1 (es) |
AU (1) | AU2009221729A1 (es) |
CA (1) | CA2716670A1 (es) |
CL (1) | CL2009000545A1 (es) |
TW (1) | TW200942552A (es) |
WO (1) | WO2009111707A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8725705B2 (en) * | 2004-09-15 | 2014-05-13 | International Business Machines Corporation | Systems and methods for searching of storage data with reduced bandwidth requirements |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
RU2404806C2 (ru) * | 2005-02-23 | 2010-11-27 | Дженентек, Инк. | Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her |
DK2132573T3 (da) | 2007-03-02 | 2014-07-14 | Genentech Inc | Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression |
US8114967B2 (en) | 2007-03-27 | 2012-02-14 | Sea Lane Biotechnologies Llc | Constructs and libraries comprising antibody surrogate light chain sequences |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP2344543A2 (en) * | 2008-10-17 | 2011-07-20 | Genentech, Inc. | Treatment method |
CN102378768A (zh) | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-3/抗-c-Met抗体 |
BRPI1014449A2 (pt) | 2009-04-07 | 2017-06-27 | Roche Glycart Ag | anticorpos biespecíficos anti-erbb-2/ anti-c-met. |
CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
JP2013532627A (ja) * | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CN103384828A (zh) * | 2010-12-23 | 2013-11-06 | 雀巢产品技术援助有限公司 | 使用基于抗体的阵列进行恶性癌症疗法的药物选择 |
SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
EP2736928B1 (en) * | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
CN117018187A (zh) | 2011-10-14 | 2023-11-10 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
EP3446707A1 (en) | 2011-12-22 | 2019-02-27 | i2 Pharmaceuticals, Inc. | Surrogate binding proteins |
AU2013258844B2 (en) * | 2012-05-10 | 2017-12-21 | Zymeworks Bc Inc. | Single-arm monovalent antibody constructs and uses thereof |
KR101911048B1 (ko) * | 2013-01-29 | 2018-10-24 | 삼성전자주식회사 | p53 활성화제 및 c-Met 억제제를 포함하는 병용 투여용 약학 조성물 |
KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
EP3800204A1 (en) | 2013-04-16 | 2021-04-07 | F. Hoffmann-La Roche AG | Pertuzumab variants and evaluation thereof |
KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
US10947319B2 (en) | 2013-11-27 | 2021-03-16 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting HER2 |
KR102194142B1 (ko) | 2014-01-20 | 2020-12-23 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물 |
KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
KR102223502B1 (ko) * | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
EP3302551B1 (en) | 2015-05-30 | 2024-06-26 | F. Hoffmann-La Roche AG | Methods of treating her2-positive previously untreated metastatic breast cancer |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
KR102313262B1 (ko) | 2016-12-28 | 2021-10-14 | 제넨테크, 인크. | 진행성 her2 발현 암의 치료 |
RS61236B1 (sr) | 2017-01-17 | 2021-01-29 | Genentech Inc | Supkutane formulacije her2 antitela |
KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
AU2020229467A1 (en) * | 2019-02-26 | 2021-08-12 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-EGFR/c-met antibodies |
CA3146933A1 (en) | 2019-09-16 | 2021-03-25 | Marcus KELLY | Radiolabeled met binding proteins for immuno-pet imaging |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) * | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5871959A (en) * | 1989-12-27 | 1999-02-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing hepatocycte growth factor/scatter factor and related cell lines |
US5362716A (en) * | 1989-12-27 | 1994-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines |
US5968509A (en) * | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
US5508192A (en) * | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) * | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5227158A (en) * | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
CA2118508A1 (en) * | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP0642580B1 (en) * | 1992-05-18 | 2002-08-21 | Genentech, Inc. | Hepatocyte growth factor variants |
US5328837A (en) * | 1992-05-18 | 1994-07-12 | Genentech, Inc. | Hepatocyte growth factor protease domain variants |
US5316921A (en) * | 1992-05-18 | 1994-05-31 | Genentech, Inc. | Single-chain hepatocyte growth factor variants |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) * | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US6027888A (en) * | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
US6543773B2 (en) * | 1998-09-22 | 2003-04-08 | Walter Mims | Card game |
US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
DK1773885T3 (da) * | 2004-08-05 | 2010-08-16 | Genentech Inc | Humaniserede anti-c-met-antagonister |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
MX2010009669A (es) * | 2008-03-06 | 2010-09-22 | Genentech Inc | Terapia de combinacion con antagonistas de c-met y egfr. |
-
2009
- 2009-03-06 US US12/399,879 patent/US20090226455A1/en not_active Abandoned
- 2009-03-06 JP JP2010549913A patent/JP2011513432A/ja not_active Withdrawn
- 2009-03-06 CL CL2009000545A patent/CL2009000545A1/es unknown
- 2009-03-06 EP EP09718259A patent/EP2260056A1/en not_active Withdrawn
- 2009-03-06 CA CA2716670A patent/CA2716670A1/en not_active Abandoned
- 2009-03-06 TW TW098107444A patent/TW200942552A/zh unknown
- 2009-03-06 AR ARP090100816A patent/AR070862A1/es unknown
- 2009-03-06 WO PCT/US2009/036344 patent/WO2009111707A1/en active Application Filing
- 2009-03-06 AU AU2009221729A patent/AU2009221729A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2260056A1 (en) | 2010-12-15 |
CL2009000545A1 (es) | 2010-10-15 |
WO2009111707A1 (en) | 2009-09-11 |
JP2011513432A (ja) | 2011-04-28 |
US20090226455A1 (en) | 2009-09-10 |
AU2009221729A1 (en) | 2009-09-11 |
CA2716670A1 (en) | 2009-09-11 |
TW200942552A (en) | 2009-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070862A1 (es) | Terapia de combinacion con antagonistas de c- met y her | |
Meng et al. | Pericytes: a double-edged sword in cancer therapy | |
ECSP11010859A (es) | Derivados de picolinamida como inhibidores de cinasa | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
DOP2011000004A (es) | Agentes y antagonistas fijadores de notch y metodos para el uso de los mismos | |
CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
AR064458A1 (es) | Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos | |
CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
PE20110008A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
UY30492A1 (es) | Anticuerpo antagonista para el tratamiento del cancer | |
PE20080663A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti-her2 | |
AR073538A1 (es) | Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf) | |
CY1115571T1 (el) | Νεες ενωσεις και μεθοδοι για θεραπεια | |
MX2009011226A (es) | Inhibidores especificos pdgfrbeta. | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
CL2014000889A1 (es) | Uso de pertuzumab, trastuzumab y quimioterapia para tratar cancer de mama her2 positivo, cancer gástrico her2 positivo y adenocarcinoma metastásico o inoperable her2 positivo; bolsa intravenosa que contiene pertuzumab y trastuzumab para tratar cancer. | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
PE20200757A1 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
GEP20146207B (en) | ANTI-cMET ANTOBODY | |
PE20091197A1 (es) | ANTAGONISTAS Bv8 COMO INHIBIDORES DE ANGIOGENESIS | |
AR075896A1 (es) | Anticuerpos anti-her (factor de crecimiento epidermico) | |
PE20110313A1 (es) | Antagonistas especificos del receptor fgf-r4 | |
UA108618C2 (uk) | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |